Haemonetics’ (HAE) “Strong-Buy” Rating Reiterated at Raymond James

Raymond James reaffirmed their strong-buy rating on shares of Haemonetics (NYSE:HAE) in a research report report published on Friday,Benzinga reports. They currently have a $115.00 price objective on the medical instruments supplier’s stock, down from their previous price objective of $120.00.

HAE has been the topic of several other reports. Bank of America downgraded shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $95.00 to $68.00 in a research report on Friday. Needham & Company LLC cut their price objective on Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Friday. JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. Barrington Research dropped their price target on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday. Finally, JMP Securities reduced their price objective on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Price Performance

NYSE HAE opened at $59.34 on Friday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.09. Haemonetics has a 1-year low of $59.09 and a 1-year high of $97.97. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of 23.36, a PEG ratio of 0.98 and a beta of 0.39. The business’s fifty day moving average price is $76.38 and its 200-day moving average price is $78.32.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, equities analysts predict that Haemonetics will post 4.59 earnings per share for the current year.

Institutional Trading of Haemonetics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC grew its position in shares of Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 632 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 240 shares during the last quarter. AlphaQuest LLC boosted its stake in Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after buying an additional 1,826 shares during the last quarter. KBC Group NV grew its holdings in Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock valued at $157,000 after buying an additional 712 shares in the last quarter. Finally, iSAM Funds UK Ltd bought a new stake in Haemonetics in the 3rd quarter worth approximately $204,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.